Skip to main content

Recent News

Actemra FDA Approved for Systemic Sclerosis Interstitial Lung Disease

Mar 05, 2021

Genentech announced yesterday that the US Food and Drug Administration approved tocilizumab (Actemra) for the treatment of Systemic Sclerosis-associated Interstitial Lung Disease (SSc-ILD), specifically indicated for the slowing the rate of decline in pulmonary function in adults SSc-ILD.

Tocilizumab is the first biologic, but second drug (following ninteninib), to be approved to curtail the worsening of SSc-ILD.

Read Article
Download available--Arthritis Myths https://t.co/2Kxpou4Fbz

Dr. John Cush @RheumNow (  View Tweet)

Mar 05, 2021
We have a robust agenda planned for RheumNow Live. Have you registered yet? https://t.co/3zMtzt4t2H https://t.co/iLNj8XEu4X
Dr. John Cush @RheumNow (  View Tweet)
Mar 05, 2021
QD Clinic - Remission Time What to do when not quite in remission https://t.co/BjALXBPVYm https://t.co/HftUANlU1b
Dr. John Cush @RheumNow (  View Tweet)
Mar 05, 2021
RheumNow LIVE VOTE Survey (RHEUMS only): What Kind of Rheumatologist are You? General Rheum? Selective Rheum? Specialized Rheum? please vote in our quick 4Q survey https://t.co/2c5fIgcJ5X https://t.co/LgK8yiXEWC
Dr. John Cush @RheumNow (  View Tweet)
Mar 05, 2021
Influenza Numbers are way down this year due to COVID mitigation methods, school/office closings, reduced travel/mobility. As of Jan 31st only 155 hospitalized with the flu (98% less than 2019-2020 flu season - 8,633 people were hospitalized with the flu) https://t.co/6c2YQKbt57?

Dr. John Cush @RheumNow (  View Tweet)

Mar 05, 2021
News Feature: Weight Loss to Avert Risk of Gout https://t.co/wzf69PvSJc https://t.co/Dph4OAC2Ar
Dr. John Cush @RheumNow (  View Tweet)
Mar 05, 2021
2021 Rheumatollgy drugs lead television advertising spending: #1 Humira ($65.8 million); #6 Xeljanz ($33.9 mill); #7 Skyrizi ($40 mill); #8 Enbrel ($25.8mill); #9 Rinvo ($12+ mill) https://t.co/Pan9Vr5kLt

Dr. John Cush @RheumNow (  View Tweet)

Mar 05, 2021

Baricitinib Therapy in Covid-19 Pneumonia

Mar 04, 2021

The NEJM has published the results of the ACCT-2 Study,  a double-blind, randomized, placebo-controlled trial evaluating baricitinib, an inhibitor of Janus kinase 1 (JAK1) and JAK2, plus remdesivir in hospitalized adults with Covid-19. The primary outcome was the time to recovery. The key secondary outcome was clinical status at day 15.

Read Article
Today the FDA approved tocilizumab (Actemra) for use in Systemic Sclerosis-Associated Interstitial Lung Disease for "Slowing the rate of decline in pulmonary function in adult patients with SSc-ILD" Rec dose is 162 mg SC q week (IV dose not approved) https://t.co/HXTRPiYEfZ

Dr. John Cush @RheumNow (  View Tweet)

Mar 04, 2021
QD Clinic - I'm Ready to Fly It's ok to Fly, go to a Resturant and come to https://t.co/9U4LaPKfJs https://t.co/R0eYO2GiPd https://t.co/Ot9RFlmsVT
Dr. John Cush @RheumNow (  View Tweet)
Mar 04, 2021
RheumNow Live is a powerful, interactive meeting delivered by researchers, educators, & clinicians. Sign up to attend virtually today. https://t.co/9IGCDMnlrb

Dr. John Cush @RheumNow (  View Tweet)

Mar 04, 2021
Comparison of MSU crystal ID, DECT scanning and US to Dx gout - study of 147 pts. Compared to the gold standard (MSU ID), Feet/ankles (87% sensitivity; 100% specificity) or knees DECT (91% & 87%) alone had best Dx accuracy. US was inferior to DECT. https://t.co/h8ctkfeadZ

Dr. John Cush @RheumNow (  View Tweet)

Mar 04, 2021
News Feature: Paucity of Effectiveness Research on Telemedicine in RA https://t.co/AoKnIZCYgA https://t.co/MCBfVoEvBX
Dr. John Cush @RheumNow (  View Tweet)
Mar 04, 2021
While RA incurrs a 2 fold risk of CHF; the use of HCQ does not add to a CHF risk. Mayo nested case-control study, compared RA w/ CHF vs nonCHF RA pts, showing HCQ use, nor duration of use, failed to increase CHF (OR: 0.96).https://t.co/Tx9jr07C7i

Dr. John Cush @RheumNow (  View Tweet)

Mar 04, 2021

Weight Loss to Avert Risk of Gout

Mar 03, 2021

Analysis of the NHANES population survey data shows weight gain during adulthood increases the risk of gout and that maintaining normal weight could reduce the overall gout risk by nearly 33%.

Obesity and gout have long been linked, but the the influence of weight changes during adulthood has not been examined. 

Read Article
We are just weeks away from RheumNow Live--will you be attending? https://t.co/vJlU0Z3Q3x https://t.co/i1BhS4JQgi
Dr. John Cush @RheumNow (  View Tweet)
Mar 03, 2021
QD Clinic - Don't Stop Believin' Rheumatic Patients Should NOT Stop DMARDs if the get COVID-19 https://t.co/0JAqwbatn0 https://t.co/3dzU1HHm5e
Dr. John Cush @RheumNow (  View Tweet)
Mar 03, 2021
News Feature: Combo Therapy Boosts Response in Uncontrolled Gout https://t.co/K6tmYWqDCg https://t.co/Li9fcLnP4f
Dr. John Cush @RheumNow (  View Tweet)
Mar 03, 2021
GSKs RCT showed otilimab (investigational anti-GM-CSF Ab) in severe COVID-19, was not superior to SOC for the primary endpoint - the proportion alive and free of respiratory failure at 28 days (but was effective in pts >70 yrs (65% vs 46%) https://t.co/OHvWGGlgKv

Dr. John Cush @RheumNow (  View Tweet)

Mar 03, 2021
×